99mtc ecdg
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00865319)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 99-technetium
Oral
No
Parenteral
No
Topical
No
Also known as
- 99mtc ecdg
- 99mtc ecdg
- 99mtc-ec-dg
- 99mtc-ec-dg
- (99m)tc ethylenedicysteine-deoxyglucose
- 99tc ec-dg
- technetium tc 99m ecdg
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01394679 | Phase 3 | Apr 1, 2013 | Cell>Point LLC |
| NCT01778218 | Phase 2 | Jan 1, 2013 | Cardiovascular Imaging Technologies, Cell>Point LLC |
| NCT01359267 | N/A | Apr 1, 2011 | University of Chicago |
| NCT00864110 | Phase 1 | Apr 1, 2010 | Camargo Pharmaceutical Services, Cell>Point LLC, Numoda, Venn Life Sciences, Yeshiva University |
| NCT00865319 | Phase 2 | Jun 1, 2009 | Camargo Pharmaceutical Services, Cell>Point LLC, Numoda, Venn Life Sciences, Yeshiva University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cell>Point LLC | For profit | 4 | 4 | 3 | 2009 |
| Camargo Pharmaceutical Services | For profit | 2 | 0 | 2 | 2009 |
| Numoda | For profit | 2 | 0 | 2 | 2009 |
| Venn Life Sciences | For profit | 2 | 0 | 2 | 2009 |
| Yeshiva University | Academic/Hospital | 2 | 0 | 2 | 2009 |
| Cardiovascular Imaging Technologies | For profit | 1 | 0 | 1 | 2013 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2011 |
7 organizations
Page 1 / 1